NeuBase Therapeutics, Inc. (NBSE): Price and Financial Metrics

NeuBase Therapeutics, Inc. (NBSE): $0.24

-0.01 (-3.44%)

POWR Rating

Component Grades













Add NBSE to Watchlist
Sign Up

Industry: Biotech



in industry

NBSE Stock Price Chart Interactive Chart >

Price chart for NBSE

NBSE Price/Volume Stats

Current price $0.24 52-week high $2.08
Prev. close $0.25 52-week low $0.17
Day low $0.24 Volume 97,600
Day high $0.25 Avg. volume 306,694
50-day MA $0.23 Dividend yield N/A
200-day MA $0.67 Market Cap 7.88M

NeuBase Therapeutics, Inc. (NBSE) Company Bio

NeuBase Therapeutics, Inc. produces and distributes pharmaceutical products. The Company offers drugs for the treatment of dominant genetic disorders and oncogenic mutations causing cancers. NeuBase Therapeutics serves patients in the United States.

NBSE Latest News Stream

Event/Time News Detail
Loading, please wait...

NBSE Latest Social Stream

Loading social stream, please wait...

View Full NBSE Social Stream

Latest NBSE News From Around the Web

Below are the latest news stories about NEUBASE THERAPEUTICS INC that investors may wish to consider to help them evaluate NBSE as an investment opportunity.

NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital

NeuBase specializes in genetic medicine therapies that target disease-triggering DNA and RNA mutations.

Yahoo | December 29, 2022

Have you been able to find a good deal on NeuBase Therapeutics Inc.’s shares?

NeuBase Therapeutics Inc. (NASDAQ:NBSE) marked $0.22 per share on Friday, up from a previous closing price of $0.21. While NeuBase Therapeutics Inc. has overperformed by 4.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NBSE fell by -92.71%, with highs and lows ranging from $3.18 to […]

US Post News | December 27, 2022

NeuBase Therapeutics GAAP EPS of -$1.04 beats by $0.04

NeuBase Therapeutics press release (NBSE): FY GAAP EPS of -$1.04 beats by $0.04.As of September 30, 2022, the Company had cash and cash equivalents of approximately $23.2…

Seeking Alpha | December 21, 2022

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022

PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments. “Fiscal year 2022 was a challenging period in our Company’s history as we faced a tightening of the broader capital markets for

Yahoo | December 21, 2022

NeuBase Therapeutics Inc. (NASDAQ:NBSE) Share Price Recovers 25.0% From Its Lows, But Can It Maintain Its Rise?

In last trading session, NeuBase Therapeutics Inc. (NASDAQ:NBSE) saw 0.13 million shares changing hands with its beta currently measuring 0.82. Company’s recent per share price level of $0.24 trading at $0.01 or 4.16% at ring of the bell on the day assigns it a market valuation of $8.25M. That closing price of NBSE’s stock is … NeuBase Therapeutics Inc. (NASDAQ:NBSE) Share Price Recovers 25.0% From Its Lows, But Can It Maintain Its Rise? Read More »

Marketing Sentinel | November 24, 2022

Read More 'NBSE' Stories Here

NBSE Price Returns

1-mo 15.94%
3-mo -14.29%
6-mo -78.18%
1-year -82.48%
3-year -96.50%
5-year -96.36%
YTD 26.18%
2022 -93.23%
2021 -59.80%
2020 -2.92%
2019 300.00%
2018 -95.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6341 seconds.